Current opinion in psychiatry · 2025
Utility of therapeutic drug monitoring in the treatment of major depressive disorder.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schoretsanitis Georgios, Paulzen Michael
Аннотация
PURPOSE OF THE NARRATIVE REVIEW: Response and remission rates in patients with major depressive disorder (MDD) treated with antidepressants are frequently not satisfying. Therapeutic drug monitoring (TDM), i.e. the quantification of antidepressant drug levels in blood and dose adjustment, is a modern and useful tool of personalized pharmacological treatment of MDD.
RECENT FINDINGS: Emerging evidence suggests that the use of TDM for antidepressants can be helpful in numerous clinical scenarios. Such scenarios include lack of treatment response, relapse, or adverse drug reactions related to antidepressants. The use of TDM is also indicated in specific patient subgroups, such as children, adolescents, pregnant women, elderly patients and patients with intellectual disabilities. Patients with polypharmacy and/or physical comorbidities may also benefit from TDM-guided antidepressant treatment. We critically reviewed TDM literature on antidepressants, summarizing therapeutic reference ranges and laboratory alert levels for antidepressants, although TDM is not equally recommended/supported for all antidepressants.
SUMMARY: The utilization of TDM as a tool for treatment optimization in clinical routine with antidepressants for patients with MDD offers a valuable method to improve safety and effectiveness. This work summarizes essential TDM knowledge for antidepressants and encourages the application of TDM as part of the clinical decision-making process.
RECENT FINDINGS: Emerging evidence suggests that the use of TDM for antidepressants can be helpful in numerous clinical scenarios. Such scenarios include lack of treatment response, relapse, or adverse drug reactions related to antidepressants. The use of TDM is also indicated in specific patient subgroups, such as children, adolescents, pregnant women, elderly patients and patients with intellectual disabilities. Patients with polypharmacy and/or physical comorbidities may also benefit from TDM-guided antidepressant treatment. We critically reviewed TDM literature on antidepressants, summarizing therapeutic reference ranges and laboratory alert levels for antidepressants, although TDM is not equally recommended/supported for all antidepressants.
SUMMARY: The utilization of TDM as a tool for treatment optimization in clinical routine with antidepressants for patients with MDD offers a valuable method to improve safety and effectiveness. This work summarizes essential TDM knowledge for antidepressants and encourages the application of TDM as part of the clinical decision-making process.